PDF(Pubmed)
Abstract：
Cutaneous melanoma (CM) is traditionally considered one of the most \"immunogenic\" tumors, eliciting a high immune response. However, despite the presence of tumor-infiltrating lymphocytes (TILs), melanoma cells use strategies to suppress antitumor immunity and avoid being eliminated by immune surveillance. The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) axis is a well-known immune escape system adopted by neoplastic cells. Therefore, immunotherapy with PD-1 and PD-L1 inhibitors is quickly becoming the main treatment approach for metastatic melanoma patients. However, the clinical utility of PD-L1 expression assessment in CM is controversial, and the interpretation of PD-L1 scores in clinical practice is still a matter of debate. Nonetheless, the recent literature data show that by adopting specific PD-L1 assessment methods in melanoma samples, a correlation between the expression of such a biomarker and a positive response to PD-1-based immunotherapy can be seen. Our review aims to describe the state-of-the-art knowledge regarding the prognostic and predictive role of PD-L1 expression in CM while also referring to possible biological explanations for the variability in its expressions and related treatment responses.
摘要：
皮肤黑色素瘤（CM）传统上被认为是最具“免疫原性”的肿瘤之一，引起高度免疫反应。然而,尽管存在肿瘤浸润淋巴细胞（TIL），黑色素瘤细胞使用策略来抑制抗肿瘤免疫并避免被免疫监视所消除。PD-1(程序性死亡-1)/PD-L1(程序性死亡-配体1)轴是肿瘤细胞采用的众所周知的免疫逃逸系统。因此,PD-1和PD-L1抑制剂的免疫治疗正迅速成为转移性黑色素瘤患者的主要治疗方法。然而,PD-L1表达评估在CM中的临床应用是有争议的，在临床实践中对PD-L1评分的解释仍然是一个有争议的问题。尽管如此，最近的文献数据表明，通过在黑色素瘤样本中采用特定的PD-L1评估方法，可以看出,此类生物标志物的表达与基于PD-1的免疫疗法的阳性应答之间存在相关性.我们的综述旨在描述关于PD-L1表达在CM中的预后和预测作用的最新知识，同时也提到其表达变异性和相关治疗反应的可能生物学解释。
